查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1909035

雄性激素剥夺疗法 (ADT) 市场规模、份额和成长分析（按 ADT 类型、适应症、给药途径、患者人群、通路和地区划分）— 2026-2033 年行业预测

Androgen Deprivation Therapy Market Size, Share, and Growth Analysis, By Type of ADT, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 189 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球雄性激素剥夺疗法市场规模预计在 2024 年达到 70.8 亿美元，从 2025 年的 74.7 亿美元增长到 2033 年的 115.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.6%。

由于前列腺癌发生率上升以及人们对荷尔蒙敏感性肿瘤的认识不断提高，全球雄性激素剥夺疗法市场正经历显着增长。药物递送技术的创新，包括长效注射剂和口服疗法，正在扩大治疗选择。除了人口老化带来的诊断率提高外，有利的报销政策和数位化监测解决方案也改善了患者获得治疗的机会。然而，潜在的心血管副作用以及开发中国家的高成本等挑战仍然是该疗法广泛应用的障碍。未来市场趋势，包括基于人工智慧的治疗优化、生物类似药的兴起以及即时荷尔蒙抑制监测技术的进步，预计将对长期临床疗效和市场潜力产生影响。

全球雄性激素剥夺疗法市场驱动因素

全球老年男性前列腺癌发生率的不断上升是推动雄性激素剥夺疗法需求成长的主要因素。雄性激素剥夺疗法仍是荷尔蒙敏感性前列腺癌（尤其是进行性或转移性病例）的主要治疗选择。此外，政府加强筛检政策以及人们对早期发现重要性的认识不断提高，也促进了治疗量的成长。这些因素共同凸显了雄性激素剥夺疗法在前列腺癌治疗中的重要作用，因为医疗保健系统正在努力满足这群患者对有效干预措施日益增长的需求。因此，预计该疗法的市场将迎来显着成长。

全球雄性激素剥夺疗法市场的限制因素

全球雄性激素剥夺疗法市场的发展受到治疗成本高昂的严重限制，尤其是新型口服抑制剂和长效注射剂的成本。这些费用往往超出开发中国家的标准保险覆盖范围和公共医疗预算，造成沉重的经济负担。此外，病患报销不足以及医疗体系的脱节进一步加剧了这个问题。因此，经济负担使得许多需要治疗的患者无法获得这些疗法，最终限制了市场整体成长及其在服务不足地区的覆盖范围。

全球雄性激素剥夺疗法市场趋势

全球雄性激素剥夺疗法市场正经历着向新一代口服荷尔蒙阻断剂的显着转变，其主要驱动力在于药物的便利性和减少就诊次数。这一趋势反映出前列腺癌治疗中，人们越来越倾向于采用分散式治疗方法，口服促性腺激素释放激素（LHRH）拮抗剂和抗雄性激素药物正逐渐成为第一线治疗方案。患者越来越多地选择口服疗法而非传统的注射疗法，因为口服疗法具有更大的治疗柔软性和更高的依从性。这些创新治疗方法的普及正在重塑市场格局，并凸显出医疗保健系统中雄性激素剥夺疗法的实施和认知方式的模式转移。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究
  • 顾客购买行为分析

全球雄性激素剥夺疗法 (ADT) 市场规模（按 ADT 类型和复合年增长率划分）（2026-2033 年）

  • GnRH类似物
  • 抗雄激素

全球雄性激素剥夺疗法 (ADT) 市场规模（按适应症和复合年增长率划分）（2026-2033 年）

  • 局限性前列腺癌
  • 进行性前列腺癌

全球雄性激素剥夺疗法 (ADT) 市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

  • 肌肉内注射
  • 皮下注射

全球雄性激素剥夺疗法 (ADT) 市场规模（按患者群体划分）及复合年增长率 (2026-2033)

  • 40至60岁的男性
  • 61至75岁的男性
  • 75岁及以上的男性

全球雄性素剥夺疗法 (ADT) 市场规模（按分销管道划分）及复合年增长率 (2026-2033)

  • 医院
  • 专科癌症诊所
  • 网路药房
  • 零售药房

全球雄性激素剥夺疗法（ADT）市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • Ferring BV
  • AstraZeneca
  • Bayer AG
  • Astellas Pharma Inc
  • Johnson & Johnson
  • Foresee Pharmaceuticals Co Ltd
  • Viatris
  • Verity Pharmaceuticals Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Tolmar Pharmaceuticals Inc

结论与建议

简介目录
Product Code: SQMIG35I2405

Global Androgen Deprivation Therapy Market size was valued at USD 7.08 Billion in 2024 and is poised to grow from USD 7.47 Billion in 2025 to USD 11.55 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The global market for androgen deprivation therapy is experiencing significant growth due to the rising incidence of prostate cancer and heightened awareness regarding hormone-sensitive tumors. Innovations in drug delivery, including long-acting injectables and oral therapies, are enhancing treatment options. Increased diagnosis rates among aging populations, alongside favorable reimbursement policies and digital monitoring solutions, are improving patient access to therapy. Nonetheless, challenges such as potential cardiac side effects and high costs in developing nations pose barriers to widespread adoption. Future trends shaping the market include AI-driven therapy optimization, the emergence of biosimilars, and advanced methods for real-time hormone suppression monitoring, all of which are poised to impact long-term clinical outcomes and market viability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older males is significantly driving the demand for androgen deprivation therapy, which remains the primary treatment choice for hormone-sensitive prostate cancer, particularly in advanced or metastatic cases. Additionally, enhanced government screening initiatives and a growing awareness surrounding the importance of early detection are contributing to higher treatment volumes. This combination of factors underscores the critical role of androgen deprivation therapy in managing prostate cancer, as healthcare systems respond to the rising need for effective interventions in this patient population. Consequently, the market for this therapy is expected to see substantial growth.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market is significantly hindered by the high costs associated with treatments, especially those involving newer oral blockers and long-acting injectables. These expenses often exceed the limits of standard insurance coverage or the allocation of public health budgets in developing nations, creating a major affordability challenge. Additionally, inadequate reimbursement options for patients, combined with poorly coordinated healthcare systems, further exacerbate this issue. As a result, the financial burden restricts access to these therapies for many individuals who need them, ultimately limiting the overall market growth and potential reach in underserved regions.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market is experiencing a significant shift towards new-generation oral hormone blockers, driven by their convenience and reduced need for frequent clinic visits. This trend represents a growing preference for decentralized treatment options in prostate cancer management, as oral LHRH antagonists and antiandrogens transition into first-line therapies. Patients are increasingly opting for oral-only therapies over traditional injectable treatments, enhancing treatment flexibility and adherence. The proliferation of these innovative therapies is reshaping the market landscape, highlighting a paradigm shift in how androgen deprivation therapy is administered and perceived within the healthcare ecosystem.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2026-2033)

  • Market Overview
  • GnRH Analogues
  • Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2026-2033)

  • Market Overview
  • Localized Prostate Cancer
  • Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intramuscular
  • Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2026-2033)

  • Market Overview
  • Men aged 40-60
  • Men aged 61-75
  • Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialized Cancer Clinics
  • Online Pharmacies
  • Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2026-2033)

  • North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • US
    • Canada
  • Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Ferring B V
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Foresee Pharmaceuticals Co Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viatris
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Verity Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tolmar Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations